DOCSLIB.ORG

(12) Patent Application Publication (10) Pub. No.: US 2005/0203111A1 David (43) Pub

Total Page：16

File Type：pdf, Size：1020Kb

Download full-text PDF Read full-text
(12) Patent Application Publication (10) Pub. No.: US 2005/0203111A1 David (43) Pub US 20050203111A1 (19) United States (12) Patent Application Publication (10) Pub. No.: US 2005/0203111A1 David (43) Pub. Date: Sep. 15, 2005 (54) COMPOSITIONS AND METHODS FOR Publication Classification PREVENTING AND TREATING SKIN AND HAIR CONDITIONS (51) Int. Cl.' .................. A61K 31/517; A61K 31/4745; A61K 31/41.96 (75) Inventor: Nathaniel E. David, San Francisco, CA (52) U.S. Cl. ...................... 514/266.1; 514/383; 514/357; (US) 514/396; 514/303 Correspondence Address: (57) ABSTRACT WILSON SONS IN GOODRICH & ROSAT 650 PAGE MILL ROAD The present invention discloses compositions and methods PALO ALTO, CA 94304-1050 (US) for the prevention and treatment of skin and hair diseases, Such as, for example, alopecia, psoriasis, and keloids. In one (73) Assignee: VVII NewCo 2003, Inc., Menlo Park, embodiment, the present invention discloses a method for CA (US) preventing and treating hair loSS by applying locally to a region lacking hair a p38C. MAP kinase inhibitor. The p38C. (21) Appl. No.: 10/799,867 MAP kinase inhibitor is preferably formulated as a gel, ointment, Spray or Solution that can be applied topically, (22) Filed: Mar. 12, 2004 transdermally, or Subcutaneously to the targeted region. Patent Application Publication Sep. 15, 2005 Sheet 1 of 4 US 2005/0203111A1 F.G. 1 Patent Application Publication Sep. 15, 2005 Sheet 2 of 4 US 2005/0203111 A1 '', FIG. 2 Patent Application Publication Sep. 15, 2005 Sheet 3 of 4 US 2005/0203111A1 FIG. 3 Patent Application Publication Sep. 15, 2005 Sheet 4 of 4 US 2005/0203111A1 FIG. 4 US 2005/0203111A1 Sep. 15, 2005 COMPOSITIONS AND METHODS FOR 0008. In particular, the present invention relates to meth PREVENTING AND TREATING SKIN AND HAIR ods for treating and/or preventing hair loSS in a patient by CONDITIONS administering to Such patient an effective amount of one or more p38 inhibitors. The p38 inhibitors are preferably BACKGROUND OF THE INVENTION administered locally to a region requiring hair regeneration 0001. The present invention relates to compositions and or prevention of hair loss. More preferably, the p38 inhibi methods for preventing and treating skin and hair condi tors are administered topically, transdermally or Subcutane tions. ously. 0002 The skin is the second largest organ in the body and 0009. The present invention also relates to methods for is of primary importance to the Survival of a mammal. The treating and/or preventing skin conditions, Such as, for skin rests on Subcutaneous tissue largely composed of a example, Vitiligo and acne, and acne Scars by administering loose mesh of collagen fiber, fat cells, and muscle tissue. An to Such a patient an effective amount of one or more p38 average adult has over 3,000 Square inches of skin Surface inhibitors. Again, the p38 inhibitors are preferably admin area. Overall, fat-free skin accounts for at least 6 percent of istered locally. More preferably, the p38 inhibitors are an individuals total weight. The density of structures in the administered topically, transdermally or Subcutaneously. skin varies considerably depending on its location. But on 0010 Examples of p38 inhibitors include, but are not average, one Square centimeter of skin contains about 10 limited to, pyridinylimidazoles, Substituted pyrazoles, Sub hair follicles, 15 Sebaceous glands, 100 Sweat glands, half a Stituted pyridyls, quinazoline derivatives, aryl ureas, het meter of blood vessels, 2 meters of nerves with 3,000 eroaryl analogues, Substituted imidazole compounds, and sensory cells at the ends of nerve fibers, 200 nerve endings to record pain, 25 pressure receptors for the perception of Substituted triazole compounds. tactile Stimuli, 2 Sensory receptorS for cold, and 12 Sensory receptors for heat. BRIEF DESCRIPTION OF THE DRAWINGS 0003. The skin of a mammal is derived from ectoderm 0011. The novel features of the invention are set forth and mesoderm layers of an embryo. These two layers give with particularity in the appended claims. A better under rise to the epidermis and dermis, respectively. The ectoderm Standing of the features and advantages of the present and mesoderm layerS also give rise to specialized append invention will be obtained by reference to the following ages including Sensory nerves, Sweat glands, and hair fol detailed description that sets forth illustrative embodiments, licles. Thus, the skin and hair follicles are physiologically in which the principles of the invention are utilized, and the related. accompanying drawings of which: 0004. The skin serves various functions including, but 0012 FIG. 1 illustrates p38 inhibitor BIRB-796. not limited to, providing flexible physical Support, main 0013 FIG. 2 illustrates p38 inhibitor CNI-1493. taining constant temperature, excreting waste materials. Such as Salts and water, producing Vitamins by photochemical 0014 FIG. 3 illustrates p38 inhibitor RDP-58. reactions in the skin, Sensory functions, providing protection 0.015 FIG. 4 illustrates p38 inhibitor VX-745. against the excesses of ultraViolet light by pigmentation Such as melanin, providing protection of organs, preventing INCORPORATION BY REFERENCE absorption of unwanted or dangerous chemicals, and pro Viding an immunological defense. 0016 All publications and patent applications mentioned in this specification are herein incorporated by reference to 0005 Hair serves similar functions. The main function of the same extent as if each individual publication or patent hair is to provide protection against heat loSS. Hair may also application was specifically and individually indicated to be act to protect the epidermis from minor abrasions and from incorporated by reference. ultraViolet light. In addition, hair may provide indication of Sexual development. It may also play an important role in DETAILED DESCRIPTION OF THE attracting mates by indicating the general health and Vitality INVENTION of an individual. Furthermore, certain body parts may con tain Specialized hairs. Specialized hair Such as eyebrows and 0017. The present invention relates to compositions and eyelashes act to protect the eyes by channeling or Sweeping methods for preventing and treating skin and hair condi away fluids, dust and debris. Nasal hair act to trap air borne tions. The compositions of the present invention include at foreign particles before they reach the lungs. These special least one p38 MAP kinase (referred to herein as “p38”) ized hairs and other hair follicles have a highly developed inhibitor. The term “p38” as used herein, refers to all nerve network around them that can provide Sensory, tactile isoforms, splicing variants, homologues, fragments, metabo information about the environment. lites, prodrugs, and mimetics of p38, both naturally occur ring and synthetic. The term “p38 inhibitor,” as used herein, 0006 There are many conditions that affect skin and hair. refers to any agent that blocks, diminishes, inhibits, hinders, Such conditions include, but are not limited to, acne, Scar limits, decreases, reduces, restricts or interferes with the ring, Vitiligo, and hair loSS. It would be desirable to identify activity of endogenous p38. A p38 inhibitor can also func novel methods and compositions for preventing and/or treat tion upstream or downstream of p38 to downregulate the ing skin and hair conditions. amount or function of p38. SUMMARY OF THE INVENTION 0018 p38 is a stress-activated protein. p38 can be 0007. The present invention relates to methods for treat activated by, for example, UV light, heat, chemical ing and/or preventing skin and hair conditions. or osmotic shock, IL-1, TNF, and endotoxins. p38 is US 2005/0203111A1 Sep. 15, 2005 one of three families of MAP kinases: the extracel 0022. To date, there have been several mechanisms and lular regulated kinases (ERKs), the c-Jun NH2 ter numerous compounds Suggested for the inhibition of p38. minal kinases or StreSS activated protein kinases Compounds that have been Suggested for the inhibition of (JNKS or SAP kinases), and the p38 MAP kinases. A p38 include pyridinylimidazoles. See Young P. R., et al., distinguishing feature of each of these kinase fami (1997).J. Biol. Chem. 272, 12116-12121; see also Bender, P. lies is that the ERKS have a TEY amino acid motif, E., (1985) J. Med. Chem. 28, 1169-1177. Examples of the JNKS or SAP kinases have a TPY amino acid pyridinylimidazoles that may inhibit p38 include 6-(4'- motif, and the p38 MAP kinases have a TGY amino fluorophenyl)-5-(4'-pyridyl)-2,3-dihydroimidazo(2,1-b)- acid motif. thia Zole and its metabolites (Sulfoxide, Sulfone), analogues, 0019. The p38 family includes four different isoforms: fragments, and mimetics. It has further been Suggested that p38C. MAP kinase (p38c), p38B MAP kinase (p38 B), p38Y the minimal structure of pyridinylimidazoles, 4-(pyridin-4- MAP kinase (p38Y), and p388 MAP kinase (p388). p38C. is yl)-5-phenylimidazole, may be sufficient to inhibit p38. See expressed ubiquitously. A shorter C-terminal truncated form Gallagher, TF, et al., (1997) Bio-Org. Med Chem. 5, 49-64. of p38C, known as Mxi-2 has also been identified in a yeast 0023 Certain 1,5-diaryl-substituted pyrazole compounds two-hybrid Screen based on its association with the tran have also been Suggested as p38 inhibitors. Such Substituted scription factor Max. p38B has been shown to have an pyrazole compounds are disclosed in U.S. Pat. No. 6,509, additional isoform, p3832 that lacks the 8 amino acid 361, assigned to Pharmacia Corporation, incorporated insertion found in p38B. Between these two variants p3832 herein by reference for all intended purposes. Additional is believed to be the major form as p38B is catalytically less pyrazole derivatives that inhibit p38 are disclosed in U.S. active. p38Y and p388 are 63% and 61% identical to p38C, Pat. No. 6,335,336, assigned to G.D. Searle & Co., incor respectively. p38Y is expressed predominantly in skeletal porated herein by reference for all intended purposes. muscle wherein p38ö is expressed predominantly in testes 0024.
Load more

Recommended publications
  • Cutaneous Manifestations of HIV Infection Carrie L
    Chapter Title Cutaneous Manifestations of HIV Infection Carrie L. Kovarik, MD Addy Kekitiinwa, MB, ChB Heidi Schwarzwald, MD, MPH Objectives Table 1. Cutaneous manifestations of HIV 1. Review the most common cutaneous Cause Manifestations manifestations of human immunodeficiency Neoplasia Kaposi sarcoma virus (HIV) infection. Lymphoma 2. Describe the methods of diagnosis and treatment Squamous cell carcinoma for each cutaneous disease. Infectious Herpes zoster Herpes simplex virus infections Superficial fungal infections Key Points Angular cheilitis 1. Cutaneous lesions are often the first Chancroid manifestation of HIV noted by patients and Cryptococcus Histoplasmosis health professionals. Human papillomavirus (verruca vulgaris, 2. Cutaneous lesions occur frequently in both adults verruca plana, condyloma) and children infected with HIV. Impetigo 3. Diagnosis of several mucocutaneous diseases Lymphogranuloma venereum in the setting of HIV will allow appropriate Molluscum contagiosum treatment and prevention of complications. Syphilis Furunculosis 4. Prompt diagnosis and treatment of cutaneous Folliculitis manifestations can prevent complications and Pyomyositis improve quality of life for HIV-infected persons. Other Pruritic papular eruption Seborrheic dermatitis Overview Drug eruption Vasculitis Many people with human immunodeficiency virus Psoriasis (HIV) infection develop cutaneous lesions. The risk of Hyperpigmentation developing cutaneous manifestations increases with Photodermatitis disease progression. As immunosuppression increases, Atopic Dermatitis patients may develop multiple skin diseases at once, Hair changes atypical-appearing skin lesions, or diseases that are refractory to standard treatment. Skin conditions that have been associated with HIV infection are listed in Clinical staging is useful in the initial assessment of a Table 1. patient, at the time the patient enters into long-term HIV care, and for monitoring a patient’s disease progression.
    [Show full text]
  • Chronic Paronychia Refers to a Skin Condition, Which Occurs Around the Nails
    Robert E. Kalb, M.D. Buffalo Medical Group, P.C. Phone: (716) 630-1102 Fax: (716) 633-6507 Department of Dermatology 325 Essjay Road Williamsville, New York 14221 PARONYCHIA (CHRONIC) Chronic paronychia refers to a skin condition, which occurs around the nails. The term chronic means that the condition can come and go over time. The word paronychia is a fancy medical term referring to the inflammation, redness and swelling that can occur around the nails. Chronic paronychia occurs most commonly in people whose hands are in a wet environment, for example nurses, bartenders, dishwashers and hairdressers. Repeated cuts and minor trauma of the skin can damage the area around the nail and in the cuticle. This minor damage allows further irritation. There can be overgrowth of various surface germs, which slow the healing process. Symptoms of chronic paronychia include loss of the cuticle, tenderness, redness and swelling. Often the nails can appear changed with rough surfaces or grooves. Sometimes the area around the nail can be colonized with a normal bacteria or yeast on the skin. Because of this, one of the treatments that is often used is a medication, which has antibiotic properties against these types of organisms. In many cases, it is not an actual infection, but simply colonization on the surface of the skin, which impedes the healing. Treatment of chronic paronychia starts by avoiding any chronic irritation or wet environments. Wearing cotton-lined gloves to wash dishes can be helpful if this is an exposure. In most cases, topical medications are used. These often involve two different creams or two different liquids.
    [Show full text]
  • Wrestling Skin Condition Report Form
    IOWA HIGH SCHOOL ATHLETIC ASSOCIATION - WRESTLING SKIN CONDITION REPORT This is the only form a referee will accept as “current, written documentation” that a skin condition is NOT communicable. National Federation wrestling rules state, “If a participant is suspended by the referee or coach of having a communicable skin disease or any other condition that makes participation appear inadvisable, the coach shall provide current written documentation from an appropriate health-care professional, stating that the suspected disease or condition is not communicable and that the athlete’s participation would not be harmful to any opponent.” “COVERING A COMMUNICABLE CONDITION SHALL NOT BE CONSIDERED ACCEPTABLE AND DOES NOT MAKE THE WRESTLER ELIGIBLE TO PARTICIPATE.” This form must be presented to the referee, or opposing head coach, AT THE TIME OF WEIGH INS or the wrestler in question will not be allowed to compete. NFHS rule 4.2.5 states, “A contestant may have documentation from an appropriate health-care professional only, indicating a specific condi- tion such as a birthmark or other non-communicable skin conditions such as psoriasis and eczema, and that documentation is valid for the season. It is valid with the understanding that a chronic condition could become secondarily infected and may require re-evaluation. ________________________________________________ from ____________________________________ High School has Wrestler’s Name (Type or Print Legibly) High School Name (Type or Print Legibly) been examined by me for the following skin condition: ___________________________________________________________ Common name of skin condition here (Note: Wrestling coaches - the most common communicable wrestling skin conditions, and their medical names, are: boils - “furuncles” ; cold sores - “herpes simplex type-1”; impetigo - “pyoderma”; pink eye - “conjunctivitis”; ringworm - “tinea corporis”.) Mark the location(s) of the condition(s) on one of the sihlouettes below.
    [Show full text]
  • Dermatologic Conditions Educational Format Faculty Expertise Required Expertise in the Field of Study
    2019 AAFP FMX Needs Assessment Body System: Integumentary Session Topic: Dermatologic Conditions Educational Format Faculty Expertise Required Expertise in the field of study. Experience teaching in the field of study is desired. Preferred experience with audience Interactive REQUIRED response systems (ARS). Utilizing polling questions and Lecture engaging the learners in Q&A during the final 15 minutes of the session are required. Expertise teaching highly interactive, small group learning environments. Case-based, with experience developing and Problem- teaching case scenarios for simulation labs preferred. Other Based workshop-oriented designs may be accommodated. A typical OPTIONAL Learning PBL room is set for 50-100 participants, with 7-8 each per (PBL) round table. Please describe your interest and plan for teaching a PBL on your proposal form. Learning Objective(s) that will close Outcome Being Professional Practice Gap the gap and meet the need Measured Physicians have knowledge 1. Evaluate the presented skin condition Learners will gaps with regard to and determine differential diagnosis submit written diagnosing and evaluating and the need for further testing or commitment to common skin diseases (e.g. referral. change statements acne, dermatitis, rosacea). 2. Counsel patients on lifestyle on the session Primary care physicians modifications and proper skin care to evaluation, often receive inadequate control flare-ups and avoid outbreaks. indicating how dermatology training in 3. Create a disease management strategy they plan to medical school and for patients with a diagnosed implement residency. dermatologic condition based on the presented practice Patients with skin disease type and severity of the condition. recommendations. often have misconceptions 4.
    [Show full text]
  • Short Anagen Syndrome: a Case Study
    Journal of Cosmetics, Dermatological Sciences and Applications, 2012, 2, 14-15 http://dx.doi.org/10.4236/jcdsa.2012.21004 Published Online March 2012 (http://www.SciRP.org/journal/jcdsa) Short Anagen Syndrome: A Case Study Martina Alés Fernández, Francisco M. Camacho Martínez Department of Dermatology, Virgen Macarena University Hospital, Seville, Spain. Email: [email protected], [email protected] Received October 31st, 2011; revised November 18th, 2011; revised November 29th, 2011 ABSTRACT Short anagen syndrome is a relatively recently described entity. This syndrome is an unusual condition where the ana- gen growth phase of hair follicles is shorter than normal. Its clinical characteristics and trichogram findings contribute to the diagnosis of this trichosis. Keywords: Anagen Syndrome 1. Case Report Three-years-old girl with low density and slow growth scalp hair that had not been cut since birth. Her birth and medical history were unremarkable. The physical ex- amination revealed short and fine brown scalp hair with decreased density in frontoparietal areas (Figure 1). The rest of the physical examination was normal, without any abnormalities in eyelashes, eyebrows, teeth, nails or skin. The hair pull test was negative. The trichogram demon- strated some dystrophic hairs, but the most important data was an increased number of telogen hairs with a consistent decreased number of anagen hairs (Figure 2). The anagen to telogen ratio (7:28) was significantly re- duced with only 25% of hairs in anagen. 2. Discussion Short anagen syndrome is a relatively recently recog- nized entity poorly documented. Short hair due to a short anagen phase was described in 1987 by Kersey as part of tricho-dental syndrome [1].
    [Show full text]
  • "Skin & Wound Management Under the Wraps"
    SKIN & WOUND MANAGEMENT UNDER THE WRAPS Providing effective treatment and protection beneath compression bandaging is necessary to promote healing. Matthew Livingston, BSN, RN, CWS, ACHRN ound management for patients pustules around hair follicles, occurs and a drier skin surface dressing, such as living with venous insuffi- due to any type of trauma to the fol- cotton batting, will reduce the fungal ciency often involves multiple licle, such as pressure or friction, chemi- outbreak. Be aware that most rashes in W 1 complexities. These variations require cal irritation, or bacterial colonization. venous disease are from stasis dermatitis, providers to consider a spectrum of Milder forms of this skin condition are not candidiasis. strategies. Some require an advanced referred to as superficial folliculitis. This In its milder form, a latex allergy knowledge of skin conditions and dif- is considered self-limiting as long as the caused by compression wraps appears as ferential diagnosis while others are de- source of the injury is reduced. Painful, an itchy rash or hives over the major- pendent on “tricks of the trade” for deep folliculitis warrants a culture to ity of the lower extremity, or just above dressing changes and the understanding isolate the type of bacteria involved, and the knee (with possible systemic effects of different dressing modalities. treatment with systemic antibiotics.1 including puffy face and full-body rash). Fungal infections including candidia- The elastic component of the multilayer The ‘Skinny’ on Skin sis present as groups of small, red open compression dressing can be replaced Several dermatological conditions re- or closed pustules around the moist with a latex-free brand.
    [Show full text]
  • Steatocystoma-Multiplex.Pdf
    Steatocystoma multiplex Description Steatocystoma multiplex is a skin disorder characterized by the development of multiple noncancerous (benign) cysts known as steatocystomas. These growths begin in the skin's sebaceous glands, which normally produce an oily substance called sebum that lubricates the skin and hair. Steatocystomas are filled with sebum. In affected individuals, steatocystomas typically first appear during adolescence and are found most often on the torso, neck, upper arms, and upper legs. These cysts are usually the only sign of the condition. However, some affected individuals also have mild abnormalities involving the teeth or the fingernails and toenails. Frequency Although the prevalence of steatocystoma multiplex is unknown, it appears to be rare. Causes Steatocystoma multiplex can be caused by mutations in the KRT17 gene. This gene provides instructions for making a protein called keratin 17, which is produced in the nails, the hair follicles, and the skin on the palms of the hands and soles of the feet. It is also found in the skin's sebaceous glands. Keratin 17 partners with a similar protein called keratin 6b to form networks that provide strength and resilience to the skin, nails, and other tissues. The KRT17 gene mutations that cause steatocystoma multiplex alter the structure of keratin 17, preventing it from forming strong, stable networks within cells. The defective keratin network disrupts the growth and function of cells in the skin and nails, including cells that make up the sebaceous glands. These abnormalities lead to the growth of sebum-containing cysts in people with steatocystoma multiplex. However, it is unclear why steatocystomas are typically the only feature of this disorder.
    [Show full text]
  • When Razor Meets Skin: a Scientific Approach to Shaving by Dr
    When Razor Meets Skin: A Scientific Approach to Shaving by Dr. Diana Howard A survey conducted by The International Dermal Institute indicates that 79 percent of male respondents say they have one or more skin problem(s) that they notice daily, and yet the selection of their shaving products rarely takes this into account. Shaving can not only result in razor burn, ingrown hairs and razor bumps, but it can lead to increased sensitization and inflammation that results in premature aging. Unfortunately, as the average man’s beard grows two mm per day, there is ample opportunity to create an inflamed skin condition during shaving. As a matter of fact, if the average man starts shaving at age 13 and continues until he is 85 years old, and assuming he spends all of five minutes shaving each day, he will devote over six months of his life to just shaving his beard. As professional skin therapists, we may not be shaving our clients, but with the ever increasing number of men in skin treatment centers, salons and spas, we need to educate them about their specific skin care needs as it relates to shaving. Problems Associated with Shaving We know that the simple act of shaving imposes constant stress on the skin. Shaving is a form of physical exfoliation that can impact the health of the skin. Razor bumps, ingrown hairs, razor burn and inflammation are just some of the visible signs of trauma that the skin endures when a razor is used on the beard. Shaving triggers a high level of visible irritation and can lead to over- exfoliation, as well as a compromised lipid barrier.
    [Show full text]
  • Keratitis-Ichthyosis-Deafness Syndrome in Association With
    Genes and skin Eur J Dermatol 2005; 15 (5): 347-52 Laura MAINTZ1 Regina C. BETZ2 Keratitis-ichthyosis-deafness syndrome Jean-Pierre ALLAM1 in association with follicular occlusion triad Jörg WENZEL1 Axel JAKSCHE3 Nicolaus FRIEDRICHS4 Thomas BIEBER1 Keratitis-Ichthyosis-Deafness syndrome is a rare congenital disorder of Natalija NOVAK1 the ectoderm caused by mutations in the connexin-26 gene (GJB2) on 1 chromosome 13q11-q12, giving rise to keratitis, erythrokeratoderma Department of Dermatology, University of and neurosensory deafness. We report the case of a 31-year-old black Bonn, Sigmund-Freud-Str. 25, 53105 Bonn, Germany male diagnosed as having KID syndrome. Sequencing analysis showed 2 Institute of Human Genetics, University of a heterozygous missense mutation D50N (148G > A) in the GJB2 gene. Bonn, Wilhelmstr. 31, 53115 Bonn, In addition to the classical features of vascularizing keratitis, erythro- Germany 3 Department of Ophthalmology, University keratoderma and congenital deafness, our patient presented a follicular of Bonn, Sigmund-Freud-Str. 25, 53105 occlusion triad with hidradenitis suppurativa (HS, alias acne inversa), Bonn, Germany acne conglobata and dissecting cellulitis of the scalp, leading to cicatri- 4 Institute of Pathology, University of Bonn, Sigmund-Freud-Str. 25, 53105 Bonn, cial alopecia and disfiguring, inflammatory vegetations of his scalp. Germany Conservative therapy such as a keratolytic, rehydrating and antiseptic external therapy, antibiotic, antimycotic and retinoids were only of Reprints: N. Novak moderate benefit, so we finally chose the curative possibility of surgery Fax: (+49) 228 287 4883 <[email protected]> therapy of the axillar papillomas and of the scalp. The inflammatory papillomatous regions of the axillae and of the scalp were radically debrided.
    [Show full text]
  • Hair and Nail Disorders
    Hair and Nail Disorders E.J. Mayeaux, Jr., M.D., FAAFP Professor of Family Medicine Professor of Obstetrics/Gynecology Louisiana State University Health Sciences Center Shreveport, LA Hair Classification • Terminal (large) hairs – Found on the head and beard – Larger diameters and roots that extend into sub q fat LSUCourtesy Health of SciencesDr. E.J. Mayeaux, Center Jr., – M.D.USA Hair Classification • Vellus hairs are smaller in length and diameter and have less pigment • Intermediate hairs have mixed characteristics CourtesyLSU Health of E.J. Sciences Mayeaux, Jr.,Center M.D. – USA Life cycle of a hair • Hair grows at 0.35 mm/day • Cycle is typically as follows: – Anagen phase (active growth) - 3 years – Catagen (transitional) - 2-3 weeks – Telogen (preshedding or rest) about 3 Mon. • > 85% of hairs of the scalp are in Anagen – Lose 75 – 100 hairs a day • Each hair follicle’s cycle is usually asynchronous with others around it LSU Health Sciences Center – USA Alopecia Definition • Defined as partial or complete loss of hair from where it would normally grow • Can be total, diffuse, patchy, or localized Courtesy of E.J. Mayeaux, Jr., M.D. CourtesyLSU of Healththe Color Sciences Atlas of Family Center Medicine – USA Classification of Alopecia Scarring Nonscarring Neoplastic Medications Nevoid Congenital Injury such as burns Infectious Systemic illnesses Genetic (male pattern) (LE) Toxic (arsenic) Congenital Nutritional Traumatic Endocrine Immunologic PhysiologicLSU Health Sciences Center – USA General Evaluation of Hair Loss • Hx is
    [Show full text]
  • Teletrichology: a New Tool During the Covid-19 Emergency Teletricología: Una Nueva Herramienta Durante La Emergencia Sanitaria Por El Covid-19
    DermatologíaCMQ2021;19(2):194-195 PERLA DERMATOPATOLÓGICA Teletrichology: A New Tool During the COVID-19 Emergency Teletricología: una nueva herramienta durante la emergencia sanitaria por el COVID-19 Sonia Sofía Ocampo-Garza,1,2 Jorge Ocampo-Candiani,1 Gabriella Fabbrocini,2 Massimiliano Scalvenzi2 y Alessia Villani2 1 Departamento de Dermatología, Hospital Universitario Dr. José Eleuterio González, Universidad Autónoma de Nuevo León, Monterrey, Nuevo León 2 Dermatology Unit, Department of Clinical Medicine and Surgery, University of Naples Federico II, Naples, Italy ABSTRACT RESUMEN Telemedicine will probably play a more permanent role during Durante la pandemia por el COVID-19 la telemedicina ha ocupado and after the COVID-19 pandemic. Teletrichology was described un rol muy importante, el cual seguramente continuará como for hair disorders including androgenetic alopecia, alopecia parte de la dermatología a nivel mundial. La teletricología se ha areata, telogen effluvium, and some scarring alopecias. We descrito para diagnosticar y tratar diferentes enfermedades del would like to share our own experience in order to encourage cuero cabelludo, entre ellas la alopecia androgenética, la alopecia the use of teletrichology among dermatologists. areata, el efluvio telógeno, así como algunas alopecias cicatricia- les. En este artículo queremos compartir con otros dermatólogos KEYWORDS: teledermatology, telemedicine, teletrichology, COVID-19, nuestra experiencia para incentivar el uso de la teletricología. trichoscopy, alopecia, hair loss. PALABRAS CLAVE: teledermatología, telemedicina, teletricología, COVID-19, tricoscopia, alopecia, pérdida de cabello. Dear editor: scarring alopecias.1 We would like to share our own ex- n late 2019 the novel coronavirus spread throughout perience in order to encourage the use of teletrichology Ithe world; causing many dermatology departments among dermatologists.
    [Show full text]
  • 371 a Acne Excoriee , 21, 22 Acneiform Disorders , 340 Acne
    Index A African American community Acne excoriee , 21, 22 cocoa butter , 302 Acneiform disorders , 340 diagnosis codes, dermatologist Acne keloidalis nuchae (AKN) , 340 visit , 301 description , 130 hair myths , 303 diagnosis , 131, 132 patient care , 304 differential diagnosis , 133 skin myths , 301–303 epidemiology , 130–131 African descent, cultural considerations histopathology , 133 description , 300 laser hair removal , 244 health services utilization , 300–301 pathogenesis , 131 misconceptions , 301 prevalence , 130–131 AGA. See Androgenetic alopecia (AGA) treatment Aging effects, ethnic skin , 248–249 fi rst line therapy , 134–135 AKN. See Acne keloidalis nuchae (AKN) minimally invasive therapy , 135 Alaluf, S. , 6 surgical , 135 Alexis, A.F. , 23 Acne vulgaris (AV) Alopecia areata , 99–100 aggravating factors , 23 Alopecia syphilitica , 101–102 clinical features , 21–23 Alpha hydroxy acids , 286–288 epidemiology , 23–24 Alster, T. , 197 management Anagen ef fl uvium (AE) , 99 oral therapy , 27 Androgenetic alopecia (AGA) , 97–98, procedural therapy , 27–28 355–356 topical therapy , 24–26 Antimalarials pathogenic factors , 23 lupus erythematosus , 55 PIH , 22 sarcoidosis , 71 vs. rosacea , 29 Aramaki, J. , 10 sequelae , 28 Aromatherapy, traditional Asian practice Acupuncture alopecia areata , 309 traditional Asian practice, cutaneous contact dermatitis , 309, 310 conditions description , 307 adverse effects , 311 phototoxic reaction , 309 description , 309 Ashy dermatosis. See Erythema evaluation process , 310 dyschromicum perstans
    [Show full text]